Viking Therapeutics Inc (VKTX) - Net Assets
Based on the latest financial reports, Viking Therapeutics Inc (VKTX) has net assets worth $639.06 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($715.73 Million) and total liabilities ($76.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VKTX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $639.06 Million |
| % of Total Assets | 89.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | 216.55% |
| 10-Year Change | 7845.7% |
| Growth Volatility | 628.06 |
Viking Therapeutics Inc - Net Assets Trend (2013–2025)
This chart illustrates how Viking Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore VKTX total assets for the complete picture of this company's asset base.
Annual Net Assets for Viking Therapeutics Inc (2013–2025)
The table below shows the annual net assets of Viking Therapeutics Inc from 2013 to 2025. For live valuation and market cap data, see how much is Viking Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $639.06 Million | -27.40% |
| 2024-12-31 | $880.28 Million | +152.65% |
| 2023-12-31 | $348.42 Million | +139.76% |
| 2022-12-31 | $145.32 Million | -28.02% |
| 2021-12-31 | $201.88 Million | -17.38% |
| 2020-12-31 | $244.34 Million | -11.83% |
| 2019-12-31 | $277.12 Million | -6.93% |
| 2018-12-31 | $297.75 Million | +2111.32% |
| 2017-12-31 | $13.46 Million | +67.41% |
| 2016-12-31 | $8.04 Million | -7.82% |
| 2015-12-31 | $8.72 Million | +139.43% |
| 2014-12-31 | $-22.13 Million | -8730.08% |
| 2013-12-31 | $-250.60K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Viking Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 84743497300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $378.00K | 0.06% |
| Other Components | $1.49 Billion | 232.56% |
| Total Equity | $639.06 Million | 100.00% |
Viking Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Viking Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Flat Glass Group Co. Ltd
SHG:601865
|
$3.35 Billion |
|
Micro-Star International Co Ltd
TW:2377
|
$3.35 Billion |
|
MERCARI INC. UNSP.ADR/1/2
F:6TP0
|
$3.35 Billion |
|
Jiangsu Phoenix Publishing & Media Corp Ltd
SHG:601928
|
$3.36 Billion |
|
ATS CORP
TO:ATS
|
$3.35 Billion |
|
Proya Cosmetics Co Ltd Class A
SHG:603605
|
$3.35 Billion |
|
Abercrombie & Fitch Company
NYSE:ANF
|
$3.35 Billion |
|
Red Rock Resorts Inc
NASDAQ:RRR
|
$3.35 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Viking Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 880,278,000 to 639,062,000, a change of -241,216,000 (-27.4%).
- Net loss of 359,639,000 reduced equity.
- Other comprehensive income increased equity by 1,166,000.
- Other factors increased equity by 117,257,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-359.64 Million | -56.28% |
| Other Comprehensive Income | $1.17 Million | +0.18% |
| Other Changes | $117.26 Million | +18.35% |
| Total Change | $- | -27.40% |
Book Value vs Market Value Analysis
This analysis compares Viking Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-71.10 | $30.80 | x |
| 2013-12-31 | $-0.06 | $30.80 | x |
| 2014-12-31 | $-5.13 | $30.80 | x |
| 2015-12-31 | $1.37 | $30.80 | x |
| 2016-12-31 | $0.49 | $30.80 | x |
| 2017-12-31 | $0.52 | $30.80 | x |
| 2018-12-31 | $5.17 | $30.80 | x |
| 2019-12-31 | $3.85 | $30.80 | x |
| 2020-12-31 | $3.37 | $30.80 | x |
| 2021-12-31 | $2.62 | $30.80 | x |
| 2022-12-31 | $1.89 | $30.80 | x |
| 2023-12-31 | $3.69 | $30.80 | x |
| 2024-12-31 | $8.07 | $30.80 | x |
| 2025-12-31 | $5.67 | $30.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Viking Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -56.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.12x
- Recent ROE (-56.28%) is above the historical average (-57.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $10.10K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-121.19K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.67 Million |
| 2015 | -268.24% | 0.00% | 0.00x | 1.77x | $-24.28 Million |
| 2016 | -183.17% | 0.00% | 0.00x | 1.81x | $-15.54 Million |
| 2017 | -152.83% | 0.00% | 0.00x | 1.64x | $-21.92 Million |
| 2018 | -7.41% | 0.00% | 0.00x | 1.02x | $-51.84 Million |
| 2019 | -9.30% | 0.00% | 0.00x | 1.03x | $-53.49 Million |
| 2020 | -16.16% | -368045.85% | 0.00x | 1.05x | $-63.93 Million |
| 2021 | -27.24% | -513877.21% | 0.00x | 1.04x | $-75.18 Million |
| 2022 | -47.39% | 0.00% | 0.00x | 1.16x | $-83.40 Million |
| 2023 | -24.65% | 0.00% | 0.00x | 1.06x | $-120.74 Million |
| 2024 | -12.49% | 0.00% | 0.00x | 1.03x | $-197.99 Million |
| 2025 | -56.28% | 0.00% | 0.00x | 1.12x | $-423.55 Million |
Industry Comparison
This section compares Viking Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $190,374,900
- Average return on equity (ROE) among peers: -53.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Viking Therapeutics Inc (VKTX) | $639.06 Million | 0.00% | 0.12x | $3.35 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $91.45 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $312.29 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $174.79 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $823.18 Million |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $540.89 Million | -31.04% | 0.29x | $3.64 Billion |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more